SeekingAlpha · Aug 6, 2026
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsChris StammThomas McCourt - CEO &...
IR
NASDAQ · IRWD
Ironwood Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$4.31
Up+$0.23 (+5.64%)
Updated Aug 15, 2026, 6:40 AM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 598.66M
- P/E ratio
- 7.07
- Dividend yield
- 0.00%
- 52-week range
- $3.02 – $4.88
- Volume
- 2.33M
- Avg. volume
- 2.12M
Price performance
IRWD price history
1M range · 21 trading sessions · Daily adjusted prices
IRWD closed at $4.31 after 21 trading sessions, up 11.66% for the selected period.
- Last close
- $4.31
- Period change
- +11.66%
- Period low
- $3.56
- Period high
- $4.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $4.03 | $4.35 | $3.96 | $4.31 | 2.33M |
| Aug 13, 2026 | $4.41 | $4.41 | $4.05 | $4.08 | 2.08M |
| Aug 12, 2026 | $4.32 | $4.505 | $4.255 | $4.32 | 2.72M |
| Aug 11, 2026 | $4.08 | $4.315 | $4.06 | $4.30 | 1.93M |
| Aug 10, 2026 | $4.17 | $4.275 | $4.04 | $4.05 | 2.18M |
| Aug 7, 2026 | $4.30 | $4.40 | $4.21 | $4.32 | 1.84M |
| Aug 6, 2026 | $4.16 | $4.375 | $3.92 | $4.26 | 3.36M |
| Aug 5, 2026 | $4.34 | $4.425 | $4.13 | $4.15 | 2.21M |
| Aug 4, 2026 | $4.53 | $4.57 | $4.275 | $4.31 | 5.77M |
| Aug 3, 2026 | $4.325 | $4.59 | $4.28 | $4.42 | 3.82M |
| Jul 31, 2026 | $3.93 | $4.275 | $3.87 | $4.23 | 3.58M |
| Jul 30, 2026 | $3.60 | $3.76 | $3.55 | $3.73 | 1.3M |
| Jul 29, 2026 | $3.80 | $3.9563 | $3.55 | $3.56 | 1.25M |
| Jul 28, 2026 | $3.90 | $3.97 | $3.76 | $3.80 | 1.82M |
| Jul 27, 2026 | $3.71 | $3.99 | $3.6868 | $3.91 | 1.93M |
| Jul 24, 2026 | $3.79 | $3.84 | $3.70 | $3.71 | 1.11M |
| Jul 23, 2026 | $3.77 | $3.84 | $3.76 | $3.79 | 1.08M |
| Jul 22, 2026 | $3.89 | $3.925 | $3.845 | $3.88 | 1.05M |
| Jul 21, 2026 | $3.87 | $3.92 | $3.81 | $3.91 | 1.16M |
| Jul 20, 2026 | $3.92 | $4.02 | $3.84 | $3.85 | 1.8M |
| Jul 17, 2026 | $3.83 | $4.01 | $3.8046 | $3.86 | 1.8M |
Latest IRWD news
The latest Smart Investors Daily articles mentioning IRWD.
Stock researchCompany · Overview
IRWD research
Overview
Company profile and research snapshot.
Company profile
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $3.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 26, 2026 | Citizens | Market Outperform | — |
| Jan 5, 2026 | Wells Fargo | Equal-Weight | — |
| Jan 5, 2026 | Citizens | Market Outperform | — |
| Nov 11, 2025 | Wells Fargo | Equal-Weight | — |
| Apr 15, 2025 | Wells Fargo | Equal-Weight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Ironwood Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-06. The following slide deck was published by Ironwood Pharmaceuticals, Inc.
ChartMill · Aug 6, 2026
Ironwood Pharmaceuticals (NASDAQ:IRWD) Raises Full-Year Guidance on Strong LINZESS Sales Despite Q2 Miss
Ironwood Pharmaceuticals posted Q2 earnings and revenue miss but raised full-year guidance and strong LINZESS sales lifted shares premarket.
Benzinga · Aug 6, 2026
Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M Est
Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2026 sales outlook from $450.000 million-$475.000 million to $460.000 million-$485.000 million vs $460.118 million estimate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
